← All trials
NCT04490915
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2020
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 29, 2024
- First posted
- Jul 29, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 165
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Neurocrine BiosciencesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.